Open Access

Difluoromethylornithine attenuates isoproterenol‑induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria‑associated membranes pathway

  • Authors:
    • Yu Zhao
    • Wei-Wei Jia
    • San Ren
    • Wei Xiao
    • Guang-Wei Li
    • Li Jin
    • Yan Lin
  • View Affiliations

  • Published online on: June 13, 2021     https://doi.org/10.3892/etm.2021.10302
  • Article Number: 870
  • Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Myocardial hypertrophy is an independent risk factor of cardiovascular diseases and is closely associated with the incidence of heart failure. In the present study, we hypothesized that difluoromethylornithine (DFMO) could attenuate cardiac hypertrophy through mitochondria‑associated membranes (MAM) and autophagy. Cardiac hypertrophy was induced in male rats by intravenous administration of isoproterenol (ISO; 5 mg/kg/day) for 1, 3,7 and 14 days. For DFMO treatment group, rats were given ISO (5 mg/kg/day) for 14 days and 2% DFMO in their water for 4 weeks. The expression of atrial natriuretic peptide (ANP) mRNA,heart parameters, apoptosis rate, fibrotic area and protein expressions of cleaved caspase3/9, GRP75, Mfn2, CypD and VDAC1 were measured to confirm the development of cardiac hypertrophy, apoptosis and autophagy induced by ISO. ANP mRNA and MAM protein expression levels were assessed by reverse transcription‑quantitative PCR and western blotting to evaluate hypertrophy and the effects of DFMO oral administration. The results demonstrated that heart parameters, ANP mRNA levels, fibrotic area and apoptosis rate were significantly increased in the heart tissue for ISO 7 and 14 day groups compared with the control group. Furthermore, treatment with DFMO significantly inhibited these indicators, and DFMO downregulated the MAM signaling pathway and upregulated the autophagy pathway in heart tissue compared with the ISO 14 day group. Overall, all ISO‑induced changes analyzed in the present study were attenuated following treatment with DFMO. The findings form this study suggested that DFMO treatment may be considered as a potential strategy for preventing ISO‑induced cardiac hypertrophy.

Introduction

The initial stage of cardiac hypertrophy is an adaptive response in volume related to hypertension, valvular disease or neurohumoral stimuli. The decompensated stage of pathological hypertrophy leads to contractile dysfunction and heart failure (HF) (1,2). Mitochondria serve crucial biological roles in excitation-contraction coupling in cardiac muscle, cellular metabolism, HF progression and myocardial ischemia/reperfusion (3-5). It has been hypothesized that abnormalities in mitochondrial function and endoplasmic reticulum (ER) may be related to cardiomyopathy (6,7).

Increasing evidence suggests that mitochondria and the ER are organelles that form an endomembrane network. Mitochondria-associated membranes (MAM) appear to be the contact point through which the ER directly communicates with mitochondria (8-10). The ER-mitochondria interface is enriched in various proteins, such as the macromolecular complex composed of voltage-dependent anion channels 1 (VDAC1), glucose regulated protein 75 (GRP75) and inositol 1,4,5-triphosphate receptor (IP3R), which regulate Ca2+ transfer from the ER to mitochondria (11,12). The crosstalk between these organelle and MAM in cardiomyopathy remains unknown and requires further investigation.

Polyamines, such as putrescine, spermidine and spermine, are involved in cell proliferation and survival and in numerous biological and pathological processes, including apoptosis, regulation of Kir channels and oxidative stress (13-15). Previous studies have reported that elevated polyamine levels are associated with cardiac hypertrophy (16,17). Certain stimuli, such as growth factors and oncogenes (hormones, Myc and Ras) can rapidly increase ornithine decarboxylase (ODC) protein level, which is a key enzyme involved in cellular polyamine biosynthesis (18,19). Difluoromethylornithine (DFMO) is an ornithine analog that has previously been reported to deplete cellular polyamines through inhibition of ODC and to promote cardioprotection by attenuating apoptosis and the NO/cGMP-dependent protein kinase-1 pathway (17,20,21). Subsequently, the present study investigated whether isoproterenol (ISO)-induced cardiomyopathy could be associated with increased apoptosis and MAM. In addition, this study examined if DFMO could be considered as an effective pharmacological method to attenuate ISO-induced cardiomyopathy and if this possible effect may be mediated by MAM signaling pathway regulation. In the present study, it was hypothesized that cardiac hypertrophy induced by ISO was associated with apoptosis and MAM and polyamine depletion by DFMO exerts a protective effect on cardiac hypertrophy.

Materials and methods

Chemicals and reagents

ISO (cat. no. 51-30-9) and DFMO (cat. no. 70052-12-9) were both purchased from Sigma-Aldrich; Merck KGaA. The TUNEL detection kit was purchased from Roche Diagnostics GmbH. The primary antibodies against cleaved caspase-3/9, caspase-3/9, VDAC1, GRP75, cyclophilin D (CypD), mitofusin 2 (Mfn2), autophagy related 5 (Atg5) and Beclin1 were obtained from Santa Cruz Biotechnology, Inc. TRIzol reagent and a PrimeScript RT Reagent kit were from Takara Biotechnology. Protein extraction kit and GAPDH antibody (both Wuhan Boster Biological Technology, Ltd.) and Masson's trichrome staining kit (Beijing Solarbio Science & Technology Co., Ltd.) were also purchased.

Animals

Healthy male Wistar rats weighing 200-250 g were used in the present study (Qiqihar Medicine University Animal Center). Rats were housed on a 12 h dark-light cycle at 23±1˚C. The study protocol was approved by the Institutional Animal Research Committee (approval no. QMU-AECC-2019-53).

Rat cardiac hypertrophy model and drug treatment

As described previously (15), rats were randomly divided into six groups (n=10 per group) as follows: i) Control group, rats were given subcutaneous injections of 0.9% saline; ii) ISO1d group, rats were given ISO (5 mg/kg/day) for 1 day; iii) ISO3d group, rats were given ISO (5 mg/kg/day) for 3 days; iv) ISO7d group, rats were given ISO (5 mg/kg/day) for 7 days; v) ISO14d group, rats were given ISO (5 mg/kg/day) for 14 days; and vi) DFMO treatment group, rats were given ISO (5 mg/kg/day) for 14 days and 2% DFMO in their water for 4 weeks. Following treatment, all rats were euthanized using 3% pentobarbital sodium (80 mg/kg) and hearts were collected for further experiments. The hearts were carefully isolated, excised and weighed in cold buffer. The ventricles were separated and weighed and the degree of ventricular hypertrophy was assessed by evaluating the heart-to-body weight (HW/BW) ratio and left ventricle-to-body weight (LVW/BW) ratio.

Quantification of fibrosis

Heart tissue samples were cut and fixed in 10% formalin for 2-3 days and embedded in paraffin at room temperature. To evaluate morphological changes, tissue samples were stained with Masson's trichrome reagent at room temperature for 120-160 min. A light microscope was used to visualize the cardiac sections at x200 magnification. The degree of collagen deposition was analyzed using Image-Pro Plus v6.0 (Media Cybernetics, Inc.). A total of ≥100 myocardial cells in each group was analyzed.

Reverse transcription quantitative (RT-q)PCR

As previously described (22,23), total RNA was isolated using TRIzol according to the manufacturer's instruction (Invitrogen; Thermo Fisher Scientific, Inc.) from left ventricular tissues at room temperature. A cDNA synthesis kit (Takara Biotechnology Inc.) and oligo(dT) primers were subsequently used to synthesize the first strand cDNA. RT-qPCR was performed using PowerUp SYBR-Green Master Mix and the results were analyzed using the StepOne™ (Thermo Fisher Scientific, Inc.) system with GAPDH as an internal control. The primers for ANP (a marker gene of cardiac hypertrophy) were as follows: forward 5'-GGGAAGTCAACCCGTCTCA-3' and reverse 5'-GGGCTC CAATCCTGTCAAT-3'. The primers for GAPDH were as follows: Forward, 5'-GAGACAGCCGCATCTTCTTG-3' and reverse, 5'-ATACGGCCAAATCCGTTCAC-3'. The thermocycling conditions were as follows: Initial denaturation at 95˚C for 30 sec; 40 cycles of annealing at 95˚C for 5 sec and extension at 60˚C for 30 sec. The relative expression levels were normalized to endogenous control and were expressed as 2-ΔΔCq (20).

Western blotting

Harvested left ventricle tissues were frozen in liquid nitrogen and stored at -80˚C until prepared as described previously (19). Heart tissues were homogenized in RIPA lysis buffer containing protease and phosphate inhibitors on ice (cat. no. P0013B; Beyotime Institute of Biotechnology) and centrifuged at 12,000 x g for 20 min at 4˚C. The protein concentration was determined using a BCA protein assay. Proteins samples were separated by electrophoresis in 10% SDS-PAGE gels (20 µg protein/lane) and transferred onto PVDF membranes. After blocking with 5% skimmed milk in Tris-buffered saline for 1.5 h at 25˚C, membranes were incubated with primary antibodies against GRP75 (1:1,000; cat. no. ab171089), VDAC1 (1:500; cat. no. ab14734), CypD (1:500; cat. no. ab231155), Mfn2 (1:500; cat. no. 11925S), GAPDH (1:1,000; cat. no. ab8245), cleaved caspase-3 (1:1,000; cat. no. 9661S), cleaved caspase-9 (1:1,000; cat. no. 20750S), Atg5 (1:500; cat. no. 2630S) and Beclin1 (1:500; cat. no. 3738S) overnight at 4˚C. The membrane was washed three times in TBST and incubated with horseradish peroxidase-conjugated secondary antibody (1:5,000; cat. no. BA1058; Wuhan Boster Biological Technology, Ltd.) in TBST for 1 h at 25˚C. The bands were detected using ECL chemiluminescence kit (cat. no. P0018M; Beyotime Institute of Biotechnology). Membranes were stripped with stripping buffer (cat. no. P0025; Beyotime Institute of Biotechnology) and re-probed with different antibodies. Relative expression levels were normalized to endogenous control GAPDH using ImageJ software (version 1.4.3.67; National Institutes of Health).

TUNEL staining

Cell apoptosis was assessed using TUNEL assay according to the manufacturers' instructions. The sections of heart tissue were cut into 6 µm slices and then dewaxed. After xylene dewaxing and ethanol dehydration, the cardiac tissue sections were incubated with 20 µg/ml proteinase K for 20 min and fluorescein-labelled dUTP for 1 h at 37˚C. Fluorescence microscopy (x200 magnification; Olympus Corporation) was used to analyze ≥100 myocardial cells in each group. Image-Pro Plus 6.0 (Media Cybernetics, Inc.) was used to calculate the results.

Immunohistochemical staining

Cardiomyocyte apoptosis was evaluated using caspase-3 and caspase-9 immunohistochemistry. Heart sections were cut into 4 µm slices according to the protocol using the citric acid method (Citrate Antigen Retrieval Solution; cat. no. P0081; Beyotime Institute of Biotechnology). Sections were blocked with 8% goat serum for 30 min at 37˚C and were incubated with caspase-3 (1:100; cat. no. ab13847, Santa Cruz Biotechnology, Inc.) and caspase-9 (1:100; cat. no. ab52298, Santa Cruz Biotechnology, Inc.) antibodies at 37˚C for 2 h. EnVision™+/HRP (cat. no. K400011-2; Dako; Agilent Technologies, Inc.) was added to sections for 1 h at 37˚C. Samples were processed using a peroxide-based substrate diaminobenzidine kit (Gene Tech Biotechnology Co., Ltd.) and nuclei were stained using haematoxylin for 1 sec at room temperature. Finally, heart sections were photographed using a light microscope (magnification, x200). The results were analyzed using Image-Pro Plus 6.0 (Media Cybernetics, Inc.).

Statistical analysis

All data were presented as the means ± standard error of the mean. One-way ANOVA followed by a Dunnett's or Student-Newman-Keuls post hoc tests were used for data analysis with GraphPad Prism 5.00 software (GraphPad Software, Inc.). P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of ISO on cardiac hypertrophy and cardiac fibrosis

To determine the effects of ISO on the development of cardiomyocyte hypertrophy, the cardiac hypertrophy model induced by ISO was established. Parameters of cardiac hypertrophy, such as HW/BW ratio, LVW/BW ratio, ANP mRNA expression were evaluated at 1, 3, 7 and 14 days following ISO injection. As presented in Fig. 1, the ratios of HW/BW and LVW/BW, the expression of ANP mRNA (Fig. 1A-C) and the areas of collagen deposition in the interstitial and perivascular (Fig. 1D and E) were significantly increased in the ISO7d and ISO14d groups compared with the control group (P<0.05 and P<0.01).

Effect of ISO on myocardial apoptosis

Cardiomyocyte apoptosis is now considered as a hallmark of heart failure (24). Using a TUNEL assay, cardiac apoptotic cells are shown by brown-stained nuclei whereas non-apoptotic cells are stained blue-green or tan shades. In the ISO7d and ISO14d groups, the apoptosis rates were significantly increased compared with the control group (P<0.05 and P<0.01, respectively; Fig. 2A and B). Furthermore, the ratios cleaved caspase-9/caspase-9 was increased in the ISO3d, ISO7d and ISO14d groups, and the ratio cleaved caspase-3/caspase-3 was significantly increased in the ISO 14d group compared with the control group (P<0.05 and P<0.01; Fig. 2C and D).

Effect of ISO on MAM pathway

It is well-known that MAMs regulate physiological functions between ER and mitochondria to maintain Ca2+ flux and lipid and metabolite exchange (25,26). To investigate the effect of ISO on myocardial cell MAM signal transduction, the expression of GRP75, VDAC1, Mfn2 and CypD was determined. The results demonstrated that GRP75 expression was increased in ISO14d group (P<0.05; Fig. 3A) whereas Mfn2 expression was unchanged in ISO groups (Fig. 3B). The protein expression of CypD was increased in ISO7d and ISO14d groups (P<0.05; Fig. 3C) and the protein expression of VDAC 1 was increased in ISO14d group (P<0.05; Fig. 3D) compared with control group.

DFMO alleviates myocardial hypertrophy and apoptosis induced by ISO

Cardiac hypertrophy and apoptosis were measured to assess the cytoprotective effect of DFMO. The ratios HW/BW and LVW/BW and the mRNA expression of ANP were significantly decreased in the DFMO treatment group compared with the ISO14d group (P<0.05; Fig. 4A-C). Furthermore, caspase-3 and caspase-9 protein expression was increased in ISO group compared with control group, which was reversed following DFMO treatment (Fig. 4D and E). In addition, the apoptosis rate was significantly decreased following DFMO treatment compared with the ISO group (P<0.05; Fig. 4F). These findings indicated that DFMO may alleviate ISO-induced myocardial hypertrophy and myocardial apoptosis.

DFMO downregulates GRP75, VDAC1 and CypD and upregulates cardiomyocyte autophagy

The effects of DFMO on the MAM pathway and autophagy were evaluated in ISO-treated rats. The results demonstrated that in rats with ISO-induced myocardial hypertrophy, DFMO could downregulate the expression of GRP75, VDAC1 and CypD and upregulate the expression of the autophagy-associated proteins Atg5 and Beclin1, leading to an attenuation of ISO effects (P<0.05 and P<0.01; Fig. 5A-E).

Discussion

The present study demonstrated that DFMO could significantly attenuate ISO-induced cardiac hypertrophy and apoptosis and downregulate the MAM pathway while increasing autophagy. It is widely known that β-adrenergic receptor activation maintains cardiac output (27), but that sustained stimulation results in heart failure (5,28). The present study demonstrated that cardiac hypertrophy, fibrosis and apoptosis were induced following ISO treatment. Cardiomyocyte apoptosis is involved in the pathogenesis and progression of cardiac dysfunction during heart failures, such as myocardial infarction, HF and ischemia reperfusion (26,27). Previous studies have suggested that increased cardiomyocyte apoptosis is implicated in the pathogenesis and development of cardiovascular complications (28-30).

Accumulating evidence showed that MAMs, including VDAC, GRP75 and CypD, are fundamental for cellular homeostasis to support mitochondrial Ca2+ signaling (31-33). Previous studies have reported that mitochondria are critical integrators of signal transduction during the development of cardiac hypertrophy (34,35). It has been demonstrated that VDAC, which is associated with the outer mitochondrial membrane, interacts with IP3R on the ER through the molecular chaperone GRP75 that is thought to participate in the refolding of proteins translocated into this organelle (36). VDAC1 may be associated with both mPTP opening and mitochondrial membrane depolarization. Importantly, VDAC1 is upregulated during cardiac hypertrophy (37,38). The results from the present study indicated that MAM pathway may play a key role during cardiac hypertrophy, and that downregulation of the MAM pathway may be cardioprotective.

Polyamines (Pas) levels are tightly regulated by ODC, which is the key enzyme controlling the biosynthesis of PAs. A previous study from our group has demonstrated that DFMO could deplete cellular polyamines via inhibition of ODC (19) and attenuate cardiomyocyte hypertrophy by inhibiting the NO/cGMP-dependent protein kinase-1 pathway and ERS pathway in vivo (20). The findings from the present study indicated DFMO treatment may prevent ISO-induced cardiac hypertrophy, fibrosis and cardiomyocyte apoptosis, and downregulate the MAM pathway.

Autophagy maintains cellular homeostasis and regulates apoptosis by degrading proteins with long half-lives or damaging organelles (39,40). The complexes formed by ATG5 and Beclin-1 proteins are the core molecular machinery for activation of the autophagy pathway (41). Previous studies have reported that MAMs serve a crucial role in autophagy. Beclin1 is a proautophagic protein that forms at specific regions of MAM in starvation-induced autophagy (42,43). To explore the effect of DFMO on autophagy, the present study evaluated the expression of Atg5 and Beclin1. The results demonstrated that Atg5 expression was significantly decreased in ISO-induced hypertrophic rat hearts, and that DFMO could significantly increase the expression of Atg5 and Beclin1. We therefore hypothesized that Atg5 and Beclin1 may promote the survival of cardiomyocytes and inhibit hypertrophy.

In summary, the present study used an animal model of ISO-induced cardiac hypertrophy to assess the protective effect of DFMO. In ISO-treated rats, the expression of MAM pathway proteins was upregulated and associated with ISO-induced cardiac hypertrophy. Importantly, DFMO was demonstrated to ameliorate cardiac hypertrophy via inhibition of the MAM pathway and activation of the autophagy pathway (Fig. 6) One potential limitation of this study would be that the effect of DFMO on heart function, including ejection fraction and fractional shortening using echocardiography, was not evaluated. Further investigation is therefore needed to understand the relationship between MAM and the cardiac function following treatment with DFMO. The findings from the present study suggested that DFMO may be considered as a potential therapeutic agent to treat cardiac hypertrophy.

Acknowledgements

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YZ and YL designed the experiments and wrote and revised the manuscript. WWJ, SR and WX performed the experiments and analyzed the data. GWL and LJ carried out the experiments and revised the manuscript. All authors read and approved the final version. YL and GWL confirm the authenticity of all the raw data.

Ethics approval and consent to participate

The experimental protocols were approved by the Committee on the Ethics of Animal Experiments of Qiqihar Medical University, China (approval no. QMU-AECC-2019-53).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Branco AF, Sampaio SF, Wieckowski MR, Sardão VA and Oliveira PJ: Mitochondrial disruption occurs downstream from - adrenergic overactivation by isoproterenol in differentiated, but not undifferentiated H9c2 cardiomyoblasts: Differential activation of stress and survival pathways. Int J Biochem Cell Biol. 45:2379–2391. 2013.PubMed/NCBI View Article : Google Scholar

2 

Berenji K, Drazner MH, Rothermel BA and Hill JA: Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol. 289:H8–H16. 2005.PubMed/NCBI View Article : Google Scholar

3 

Forte M, Schirone L, Ameri P, Basso C, Catalucci D, Modica J, Chimenti C, Crotti L, Frati G, Rubattu S, et al: The role of mitochondrial dynamics in cardiovascular diseases. Br J Pharmacol. 15:1–17. 2020.PubMed/NCBI View Article : Google Scholar

4 

Wyss RK, Méndez-Carmona N, Sanz MN, Arnold M, Segiser A, Fiedler GM, Carrel TP, Djafarzadeh S, Tevaearai Stahel HT and Longnus SL: Mitochondrial integrity during early reperfusion in an isolated rat heart model of donation after circulatory death-consequences of ischemic duration. J Heart Lung Transplant. 38:647–657. 2019.PubMed/NCBI View Article : Google Scholar

5 

Dudek J, Hartmann M and Rehling P: The role of mitochondrial cardiolipin in heart function and its implication in cardiac disease. Biochim Biophys Acta Mol Basis Dis. 1865:810–821. 2019.PubMed/NCBI View Article : Google Scholar

6 

Raut GK, Manchineela S, Chakrabarti M, Bhukya CK, Naini R, Venkateshwari A, Reddy VD, Mendonza JJ, Suresh Y, Nallari P, et al: Imine stilbene analog ameliorate isoproterenol-induced cardiac hypertrophy and hydrogen peroxide-induced apoptosis. Free Radic Biol Med. 153:80–88. 2020.PubMed/NCBI View Article : Google Scholar

7 

Wang S, Binder P, Fang Q, Wang Z, Xiao W, Liu W and Wang X: Endoplasmic reticulum stress in the heart: Insights into mechanisms and drug targets. Br J Pharmacol. 175:1293–1304. 2018.PubMed/NCBI View Article : Google Scholar

8 

Rieusset J: Mitochondria and endoplasmic reticulum: Mitochondria-endoplasmic reticulum interplay in type 2 diabetes pathophysiology. Int J Biochem Cell Biol. 43:1257–1262. 2011.PubMed/NCBI View Article : Google Scholar

9 

Monteiro JP, Oliveira PJ and Jurado AS: Mitochondrial membrane lipid remodeling in pathophysiology: A new target for diet and therapeutic interventions. Prog Lipid Res. 52:513–528. 2013.PubMed/NCBI View Article : Google Scholar

10 

Tang LL, Wang JD, Xu TT, Zhao Z, Zheng JJ, Ge RS and Zhu DY: Mitochondrial toxicity of perfluorooctane sulfonate in mouse embryonic stem cell-derived cardiomyocytes. Toxicology. 382:108–116. 2017.PubMed/NCBI View Article : Google Scholar

11 

Sironi L, Restelli LM, Tolnay M, Neutzner A and Frank S: Dysregulated interorganellar crosstalk of mitochondria in the pathogenesis of Parkinson's disease. Cells. 9(233)2020.PubMed/NCBI View Article : Google Scholar

12 

Murata D, Arai K, Iijima M and Sesaki H: Mitochondrial division, fusion and degradation. J Biochem. 167:233–241. 2020.PubMed/NCBI View Article : Google Scholar

13 

Ou Y, Wang SJ, Li D, Chu B and Gu W: Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci USA. 113:E6806–E6812. 2016.PubMed/NCBI View Article : Google Scholar

14 

Pegg AE: Functions of polyamines in mammals. J Biol Chem. 291:14904–14912. 2016.PubMed/NCBI View Article : Google Scholar

15 

Murray Stewart T, Dunston TT, Woster PM and Casero RA Jr: Polyamine catabolism and oxidative damage. J Biol Chem. 293:18736–18745. 2018.PubMed/NCBI View Article : Google Scholar

16 

Chen M, Xin J, Liu B, Luo L, Li J, Yin W and Li M: Mitogen-activated protein kinase and intracellular polyamine signaling is involved in TRPV1 activation-induced cardiac hypertrophy. J Am Heart Assoc. 5(e003718)2016.PubMed/NCBI View Article : Google Scholar

17 

Lin Y, Zhang X, Wang L, Zhao Y, Li H, Xiao W, Xu C and Liu J: Polyamine depletion attenuates isoproterenol-induced hypertrophy and endoplasmic reticulum stress in cardiomyocytes. Cell Physiol Biochem. 34:1455–1465. 2014.PubMed/NCBI View Article : Google Scholar

18 

Casero RA Jr, Murray Stewart T and Pegg AE: Polyamine metabolism and cancer: Treatments, challenges and opportunities. Nat Rev Cancer. 18:681–695. 2018.PubMed/NCBI View Article : Google Scholar

19 

Lin Y, Liu JC, Zhang XJ, Li GW, Wang LN, Xi YH, Li HZ, Zhao YJ and Xu CQ: Downregulation of the ornithine decarboxylase/polyamine system inhibits angiotensin-induced hypertrophy of cardiomyocytes through the NO/cGMP-dependent protein kinase type-I pathway. Cell Physiol Biochem. 25:443–450. 2010.PubMed/NCBI View Article : Google Scholar

20 

Pegg AE: Regulation of ornithine decarboxylase. J Biol Chem. 281:14529–14532. 2006.PubMed/NCBI View Article : Google Scholar

21 

Lin Y, Zhang X, Xiao W, Li B, Wang J, Jin L, Lian J, Zhou L and Liu J: Endoplasmic reticulum stress is involved in DFMO attenuating isoproterenol-induced cardiac hypertrophy in rats. Cell Physiol Biochem. 38:1553–1562. 2016.PubMed/NCBI View Article : Google Scholar

22 

Jiang G, Gong H, Niu Y, Yang C, Wang S, Chen Z, Ye Y, Zhou N, Zhang G, Ge J, et al: Identification of amino acid residues in angiotensin ii type 1 receptor sensing mechanical stretch and function in cardiomyocyte hypertrophy. Cell Physiol Biochem. 37:105–116. 2015.PubMed/NCBI View Article : Google Scholar

23 

Wang W, Zhang H, Xue G, Zhang L, Zhang W, Wang L, Lu F, Li H, Bai S, Lin Y, et al: Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool. Oxid Med Cell Longev. 2014(457429)2014.PubMed/NCBI View Article : Google Scholar

24 

Braunwald E: Heart failure. JACC Heart Fail. 1:1–20. 2013.PubMed/NCBI View Article : Google Scholar

25 

Perrone M, Caroccia N, Genovese I, Missiroli S, Modesti L, Pedriali G, Vezzani B, Vitto VAM, Antenori M, Lebiedzinska-Arciszewska M, et al: The role of mitochondria-associated membranes in cellular homeostasis and diseases. Int Rev Cell Mol Biol. 350:119–196. 2020.PubMed/NCBI View Article : Google Scholar

26 

Imaeda A, Tanaka S, Tonegawa K, Fuchigami S, Obana M, Maeda M, Kihara M, Kiyonari H, Conway SJ, Fujio Y, et al: Myofibroblast β2 adrenergic signaling amplifies cardiac hypertrophy in mice. Biochem Biophys Res Commun. 510:149–155. 2019.PubMed/NCBI View Article : Google Scholar

27 

de Lucia C, Eguchi A and Koch WJ: New insights in cardiac β-adrenergic signaling during heart failure and aging. Front Pharmacol. 9(904)2018.PubMed/NCBI View Article : Google Scholar

28 

Ferrara N, Komici K, Corbi G, Pagano G, Furgi G, Rengo C, Femminella GD, Leosco D and Bonaduce D: β-adrenergic receptor responsiveness in aging heart and clinical implications. Front Physiol. 4(396)2014.PubMed/NCBI View Article : Google Scholar

29 

Ramani D, De Bandt JP and Cynober L: Aliphatic polyamines in physiology and diseases. Clin Nutr. 33:14–22. 2014.PubMed/NCBI View Article : Google Scholar

30 

Li Y and Liu X: The inhibitory role of Chinese materia medica in cardiomyocyte apoptosis and underlying molecular mechanism. Biomed Pharmacother. 118(109372)2019.PubMed/NCBI View Article : Google Scholar

31 

Huang P, Fu J, Chen L, Ju C, Wu K, Liu H, Liu Y, Qi B, Qi B and Liu L: Redd1 protects against post infarction cardiac dysfunction by targeting apoptosis and autophagy. Int J Mol Med. 44:2065–2076. 2019.PubMed/NCBI View Article : Google Scholar

32 

Takeshima H, Venturi E and Sitsapesan R: Takeshima1 H, Venturi E and Sitsapesan R: New and notable ion-channels in the sarcoplasmic/endoplasmic reticulum: Do they support the process of intracellular Ca2+ release? J Physiol. 593:3241–3251. 2015.PubMed/NCBI View Article : Google Scholar

33 

Sun D, Chen X, Gu G, Wang J and Zhang J: Potential roles of mitochondria-associated ER membranes (MAMs) in traumatic brain injury. Cell Mol Neurobiol. 37:1349–1357. 2017.PubMed/NCBI View Article : Google Scholar

34 

Dingreville F, Panthu B, Thivolet C, Ducreux S, Gouriou Y, Pesenti S, Chauvin MA, Chikh K, Errazuriz-Cerda E, Van Coppenolle F, et al: Differential effect of glucose on ER-mitochondria Ca2+ exchange participates in insulin secretion and glucotoxicity-mediated dysfunction of β-cells. Diabetes. 68:1778–1794. 2019.PubMed/NCBI View Article : Google Scholar

35 

Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N and Hall MN: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc Natl Acad Sci USA. 110:12526–12534. 2013.PubMed/NCBI View Article : Google Scholar

36 

Roman B, Kaur P, Ashok D, Kohr M, Biswas R, O'Rourke B, Steenbergen C and Das sS: Nuclear-mitochondrial communication involving miR-181c plays an important role in cardiac dysfunction during obesity. J Mol Cell Cardiol. 144:87–96. 2020.PubMed/NCBI View Article : Google Scholar

37 

Szabadkai G, Bianchi K, Várnai P, De Stefani D, Wieckowski MR, Cavagna D, Nagy AI, Balla T and Rizzuto R: Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol. 175:901–911. 2006.PubMed/NCBI View Article : Google Scholar

38 

Mitra A, Basak T, Datta K, Naskar S, Sengupta S and Sarkar S: Role of α-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction. Cell Death Dis. 4(e582)2013.PubMed/NCBI View Article : Google Scholar

39 

Javadov S, Rajapurohitam V, Kilić A, Zeidan A, Choi A and Karmazyn M: Anti-hypertrophic effect of NHE-1 inhibition involves GSK-3beta-dependent attenuation of mitochondrial dysfunction. J Mol Cell Cardiol. 46:998–1007. 2009.PubMed/NCBI View Article : Google Scholar

40 

Li X, Lu J, Xu Y, Wang J, Qiu X, Fan L, Li B, Liu W, Mao F, Zhu J, et al: Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease. Acta Pharm Sin B. 10:646–666. 2020.PubMed/NCBI View Article : Google Scholar

41 

Cheon SY, Kim H, Rubinsztein DC and Lee JE: Autophagy, cellular aging and age-related human diseases. Exp Neurobiol. 28:643–657. 2019.PubMed/NCBI View Article : Google Scholar

42 

Mizushima N, Yoshimori T and Ohsumi Y: The role of Atg proteins in autophagosome formation. Annu Rev Cell Dev Biol. 27:107–132. 2011.PubMed/NCBI View Article : Google Scholar

43 

Gelmetti V, De Rosa P, Torosantucci L, Marini ES, Romagnoli A, Di Rienzo M, Arena G, Vignone D, Fimia GM and Valente EM: PINK1 and BECN1 relocalize at mitochondria-associated membranes during mitophagy and promote ER-mitochondria tethering and autophagosome formation. Autophagy. 13:654–669. 2017.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

August-2021
Volume 22 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhao Y, Jia W, Ren S, Xiao W, Li G, Jin L and Lin Y: Difluoromethylornithine attenuates isoproterenol‑induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria‑associated membranes pathway. Exp Ther Med 22: 870, 2021
APA
Zhao, Y., Jia, W., Ren, S., Xiao, W., Li, G., Jin, L., & Lin, Y. (2021). Difluoromethylornithine attenuates isoproterenol‑induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria‑associated membranes pathway. Experimental and Therapeutic Medicine, 22, 870. https://doi.org/10.3892/etm.2021.10302
MLA
Zhao, Y., Jia, W., Ren, S., Xiao, W., Li, G., Jin, L., Lin, Y."Difluoromethylornithine attenuates isoproterenol‑induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria‑associated membranes pathway". Experimental and Therapeutic Medicine 22.2 (2021): 870.
Chicago
Zhao, Y., Jia, W., Ren, S., Xiao, W., Li, G., Jin, L., Lin, Y."Difluoromethylornithine attenuates isoproterenol‑induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria‑associated membranes pathway". Experimental and Therapeutic Medicine 22, no. 2 (2021): 870. https://doi.org/10.3892/etm.2021.10302